However, Most Surveyed Neurologists Indicate They Are Only Moderately Satisfied With Topiramate’s Accessibility, According to Findings from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the prophylactic treatment of chronic migraine, the highest proportion of surveyed neurologists select topiramate (Ortho-McNeil/Janssen-Cilag’s Topamax, generics) as having the best overall clinical profile when compared to other currently-available therapies.
The findings from Decision Resources’ analysis of the chronic migraine drug market also reveal that topiramate was chosen by the highest percentage of neurologists (55 percent) and MCO pharmacy directors (40 percent) as the most efficacious current therapy for chronic migraine. This response is consistent with topiramate’s status among interviewed experts as one of the most efficacious therapies for chronic migraine and its position as the indication’s sales leader. Topiramate and onabotulinumtoxinA (Allergan’s Botox) are the only prophylactic therapies to demonstrate efficacy in multiple placebo-controlled clinical trials with chronic migraineurs.
However, although topiramate was chosen by the most surveyed neurologists as having the best overall clinical profile, neurologists are only moderately satisfied with its accessibility.
“The 55 percent of neurologists who chose topiramate as having the best overall clinical profile indicated intermediate satisfaction with the out-of-pocket costs, cost controls and overall cost of the drug, likely because the drug became available generically only in 2009,” said Decision Resources Analyst Anne-Elise Tobin, Ph.D. “Also, individual patients may still have variable coverage of the drug, depending on whether the patient’s plan has reevaluated its tiering and granted it more favorable placement.”
The findings also reveal that, despite higher diagnosis and drug-treatment rates, the chronic migraine patient population comprised about one-third of sales in the overall migraine drug market in 2009, owing to a small prevalent population. Last year, Allergan’s Botox became the first drug specifically approved for the prevention of chronic migraine. Surveyed U.S. specialists, many of whom already administer Botox off-label, express enthusiasm about the expanded labeling and Decision Resources expects that the approval of Botox, coupled with ongoing educational programs, will increase the diagnosis and treatment of chronic migraine across the world’s major pharmaceutical markets.
Decision Resources’ Robust Market Forecast and Opportunities Analysis
Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
CONTACT:
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Clinical Trials Pharmaceutical Other Health General Health
MEDIA:
| Logo |